Overactive Bladder in Males

Overview

Journal Ther Adv Urol

Publisher Sage Publications

Date 2011 Jul 27

PMID 21789068

Citations 7

Authors

Roger R Dmochowski

Alex Gomelsky

Affiliations

Soon will be listed here.

Abstract

The prevalence of overactive bladder (OAB) symptoms is considerable in both men and women and the impact on quality of life (QOL) is equally substantial. Ironically, despite nearly equal prevalence, OAB symptoms in men are infrequently treated, and often with medical therapies aimed at bladder outlet obstruction (BOO). In this review, we examine the pathophysiology of OAB and its evaluation in the context of benign prostatic hypertrophy and concomitant BOO. We then consider the efficacy and safety of individual therapeutic options for lower urinary tract symptoms in men, focusing on the mainstays of medical therapy: α-adrenergic blockers, 5-α reductase inhibitors, and antimuscarinic agents. Finally, we aim to comment on new therapeutic strategies and targets that may one day be available for the treatment of male OAB.

Citing Articles

Adverse Effects of Intravesical OnabotulinumtoxinA Injection in Patients with Idiopathic Overactive Bladder or Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Studies.

Yu P, Wang C Toxins (Basel). 2024; 16(8).

PMID: 39195753 PMC: 11359369. DOI: 10.3390/toxins16080343.

Anesthetic options for Rezūm water vapor therapy Is minimal sedation tolerable for a minimally invasive procedure?.

Bal D, Urichuk M, Panchendrabose K, Ramjiawan R, Shah J, Gebru N Can Urol Assoc J. 2024; 18(5):E137-E141.

PMID: 38319606 PMC: 11152594. DOI: 10.5489/cuaj.8535.

PATTERN OF OVERACTIVE BLADDER IN SOUTHEAST NIGERIA.

Odoemene A J West Afr Coll Surg. 2015; 4(3):100-20.

PMID: 26457269 PMC: 4553233.

Inhibition of NMDAR reduces bladder hypertrophy and improves bladder function in cyclophosphamide induced cystitis.

Liu M, Shen S, Kendig D, Mahavadi S, Murthy K, Grider J J Urol. 2015; 193(5):1676-83.

PMID: 25572034 PMC: 4861050. DOI: 10.1016/j.juro.2014.12.092.

Usage results of a mobile app for managing urinary incontinence.

Pepper J, Zhang A, Li R, Wang X J Urol. 2014; 193(4):1292-7.

PMID: 25308623 PMC: 8136036. DOI: 10.1016/j.juro.2014.10.009.

References

Abrams P, Schulman C, VAAGE S . Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group. Br J Urol. 1995; 76(3):325-36. DOI: 10.1111/j.1464-410x.1995.tb07709.x. View

Hu T, Wagner T, Bentkover J, Leblanc K, Zhou S, Hunt T . Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology. 2004; 63(3):461-5. DOI: 10.1016/j.urology.2003.10.037. View

McConnell J, Roehrborn C, Bautista O, Andriole Jr G, Dixon C, Kusek J . The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003; 349(25):2387-98. DOI: 10.1056/NEJMoa030656. View

Irwin D, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S . Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006; 50(6):1306-14. DOI: 10.1016/j.eururo.2006.09.019. View

Pontari M, McNaughton-Collins M, OLeary M, Calhoun E, Jang T, Kusek J . A case-control study of risk factors in men with chronic pelvic pain syndrome. BJU Int. 2005; 96(4):559-65. DOI: 10.1111/j.1464-410X.2005.05684.x. View

OReilly B, Kosaka A, CHANG T, Ford A, Popert R, McMahon S . A quantitative analysis of purinoceptor expression in the bladders of patients with symptomatic outlet obstruction. BJU Int. 2001; 87(7):617-22. DOI: 10.1046/j.1464-410x.2001.02179.x. View

Nishino Y, Masue T, Miwa K, Takahashi Y, Ishihara S, Deguchi T . Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. BJU Int. 2006; 97(4):747-51, discussion 751. DOI: 10.1111/j.1464-410X.2006.06030.x. View

Christ G, Day N, Day M, Zhao W, Persson K, Pandita R . Increased connexin43-mediated intercellular communication in a rat model of bladder overactivity in vivo. Am J Physiol Regul Integr Comp Physiol. 2003; 284(5):R1241-8. DOI: 10.1152/ajpregu.00030.2002. View

Benner J, Becker R, Fanning K, Jumadilova Z, Bavendam T, Brubaker L . Bother related to bladder control and health care seeking behavior in adults in the United States. J Urol. 2009; 181(6):2591-8. DOI: 10.1016/j.juro.2009.02.018. View

10.

Levin R, Longhurst P, Monson F, Kato K, Wein A . Effect of bladder outlet obstruction on the morphology, physiology, and pharmacology of the bladder. Prostate Suppl. 1990; 3:9-26. DOI: 10.1002/pros.2990170503. View

11.

Daniel E, Cowan W, Daniel V . Structural bases for neural and myogenic control of human detrusor muscle. Can J Physiol Pharmacol. 1983; 61(11):1247-73. DOI: 10.1139/y83-183. View

12.

Nickel J . Role of alpha1-blockers in chronic prostatitis syndromes. BJU Int. 2008; 101 Suppl 3:11-6. DOI: 10.1111/j.1464-410X.2008.07496.x. View

13.

Irwin D, Milsom I, Kopp Z, Abrams P, Artibani W, Herschorn S . Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: impact of overactive bladder. Eur Urol. 2009; 56(1):14-20. DOI: 10.1016/j.eururo.2009.02.026. View

14.

Coyne K, Sexton C, Irwin D, Kopp Z, Kelleher C, Milsom I . The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008; 101(11):1388-95. DOI: 10.1111/j.1464-410X.2008.07601.x. View

15.

Haferkamp A, Mundhenk J, Bastian P, Reitz A, Dorsam J, Pannek J . Increased expression of connexin 43 in the overactive neurogenic detrusor. Eur Urol. 2004; 46(6):799-805. DOI: 10.1016/j.eururo.2004.08.020. View

16.

Wang H, Lee S, DAY N, Christ G . Gap junction channel activity in cultured human bladder smooth muscle cell pairs: gating and unitary conductances. Urology. 2001; 57(6 Suppl 1):111. DOI: 10.1016/s0090-4295(01)01042-1. View

17.

Kaplan S . Update on the american urological association guidelines for the treatment of benign prostatic hyperplasia. Rev Urol. 2007; 8 Suppl 4:S10-7. PMC: 1765043. View

18.

Lowe F . Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin Ther. 2005; 26(11):1701-13. DOI: 10.1016/j.clinthera.2004.11.006. View

19.

Roehrborn C, Abrams P, Rovner E, Kaplan S, Herschorn S, Guan Z . Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU Int. 2006; 97(5):1003-6. DOI: 10.1111/j.1464-410X.2006.06068.x. View

20.

Roehrborn C, Kaplan S, Kraus S, Wang J, Bavendam T, Guan Z . Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. Urology. 2008; 72(5):1061-7. DOI: 10.1016/j.urology.2008.06.067. View